An interventional study of Gefapixant Citrate in Chronic Cough, sponsored by Nagoya City University. Recruiting at 2 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Nagoya City University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing gefapixant in Chronic Cough — 2 open to participants now, 2 under way, none of them phase 3. Gefapixant · Chronic Cough.
Among the 15 studies testing gefapixant in Chronic Cough, this one is the 8th largest by planned enrollment, is one of 2 that started in 2024, is the only one with no phase, and was the 15th registered.
142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.
Browse Chronic Cough studies →2 of the 15 studies testing gefapixant in Chronic Cough are open now, in 2 countries. Recruiting first, the newest first:
Stuart Mazzone · Sites in Australia
Ages 18–65
By country, each count listing its studies:
Gefapixant: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 63 is close to the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 63 across the 15 interventional studies. Of the 13 that completed or were terminated, 13 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 4 most frequent:
Nagoya City University is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Nagoya City University has 1 study filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing gefapixant in Chronic Cough, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.
Chronic cough has a high global prevalence, but appears to be poorly recognized. Most patients respond to specific treatments against causes of chronic cough. Meanwhile, cough is refractory to such treatments by approximately 20% of patients and they are regarded as "refractory chronic cough (RCC). Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with RCC through the inhibition of ATP transmission to afferent nerves. According to the COUGH-1 and COUGH-2, taste disturbance is the most frequent adverse event by gefapixant, with the incidence of 59.3% in COUGH-1 and 68.9% in COUGH-2, respectively. Although 45 mg of gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear in RCC and UCC. Furthermore, both taste disturbance and the improvement of cough by gefapixant would be associated with treatment satisfaction. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. The investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients. Furthermore, the investigator would like to evaluate the association of taste disturbance with cough-specific QoL in the real-world clinical practice. In addition, there are no biomarkers available that can predict the efficacy of the improvement of cough by gefapixant. The investigator will also explore biomarkers that can be helpful in predicting well response to gefapixant in RCC and UCC patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take 45mg of gefapixiant twice a day for 12 weeks.
Drug: Gefapixant Citrate
An additional treatment of gefapixiant will be performed for 12 weeks.
Also known as: LYFNUA Tablets
Treatment satisfaction
To evaluate the change in treatment satisfaction with the initiation of gefapixiant and to determine factors related to treatment satisfaction by gefapixant. The investigator will assess overall treatment satisfaction using 5-point Likert scale (1. Very dissatisfied 2. Dissatisfied 3. Neutral 4. Satisfied 5. Very Satisfied) at enrolment and 12 weeks after commencing gefapixant from all participants. The investigator will compare the rate of "Satisfaction" (4. Satisfied 5. Very Satisfied) before and after the initiation of gefapixant using the McNemar analysis. Taste disturbance will also be assessed using the Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) classification with slight modification (Grade 0: No change in taste. Grade 1: Altered taste but no change in diet, Grade 2: Altered taste with change in diet; noxious or unpleasant taste; loss of taste; Grade 3 Cease to gefapixant due to altered taste)
Time frame: 12 weeks
The change in cough-specific quality of life and clinical factors
To evaluate the association between the change in cough-specific quality of life (QoL) using the Leicester Cough Questionnaire (LCQ) and the change in clinical factors with gefapixant. The LCQ questionnaire consists of 19 items with 3 domains. It ranges from 3 to 21, with higher scores indicate better cough-specific QoL.
Time frame: 12 weeks
The changes in the core five tastes
To evaluate the changes in the core five tastes such as sweet, sour, bitter, salty, and umami with the initiation of gefapixiant and to determine what tastes are associated with the change in cough-specific quality of life (QoL). The investigator will evaluate threshold of five basic taste perception with a whole-mouth method using a series of twofold dilutions of the taste solutions including sweet (sucrose), salty (NaCl), sour (tartaric acid), bitter (quinine HCl), and umami (monosodium L-glutamate). These measurements will be conducted before and 12 weeks after the initiation of gefapixant to investigate which taste will be affected by gefapixant. The investigator will prepare for 8 doubling concentrations of these 5 tastes, respectively. Sucrose, citric acid, NaCl, Munosodium glutamate, and quinine HCL will be used to make solutions.
Time frame: 12 weeks
Seeking biomarkers
To seek biomarkers that can predict the change of cough-specific quality of life by gefapixant. Lack of zinc and copper are well-known cause of taste disturbance. Copper/zinc ratio is reported as a good diagnostic marker for taste disorders. Thus, the investigator thinks that they may be associated with the development of taste disturbance by gefapixant. The investigator will measure them because their levels will be helpful when considering the additional zinc therapy for taste disorder in clinical practice. The investigator will also use airway immune cells obtained from sputum samples to measure the expression CD 39 and CD 73 in sputum.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2026, 15 months after the start.
Of 21 interventional studies with no phase under Chronic Cough, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 48. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gefapixant
Nagoya City University